Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc. has demonstrated a robust growth trajectory, with a 98% revenue increase to $13.1 million in the third quarter, driven primarily by a substantial 70% year-over-year growth in its surgeon user base and steady productivity per surgeon. The company is strategically positioned to capitalize on the expansive $13.4 billion U.S. lumbar fusion market, with upcoming plans to penetrate the cervical segment, which presents an additional opportunity for approximately 373,000 patients. Furthermore, Carlsmed's impressive gross margin of 75.9%, exceeding forecasts, reflects improved operational efficiency bolstered by lower manufacturing costs and reduced inventory expenses, contributing to a sustained revenue compound annual growth rate (CAGR) of over 50% anticipated through 2028.

Carlsmed Inc faces several challenges contributing to a negative outlook, including projected cervical revenue estimates for FY26 that fall short of internal expectations, highlighting potential market penetration issues. Additionally, concerns arise from slower adoption rates of the Aprevo technology among new surgeons, stagnant spine market growth, and possible accelerated pricing pressure on average selling prices (ASP). The company's financial health is further compromised by an EBITDA loss of $30.7 million, indicating significant operating expense challenges that could impair future profitability and market competitiveness.